✨ Onyx Summary enGene Holdings announced it will host a conference call and webcast on November 11, 2025, to present new preliminary data from the pivotal cohort of its ongoing LEGEND trial evaluating detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer. Supporting materials, including a slide deck and replay, will be
✨ Onyx Summary Perspective Therapeutics reported a third-quarter 2025 net loss of $26.0 million and ended the period with $174 million in cash, providing funding into late 2026. The company advanced multiple clinical programs, including strong interim safety and efficacy data for [212Pb]VMT-α-NET in neuroendocrine tumors, ongoing studies of
✨ Onyx Summary Lexicon Pharmaceuticals announced new data from the SOTA P CARDIA trial presented at AHA 2025 showing that sotagliflozin significantly improved cardiac structure, diastolic function, exercise capacity, and quality of life in heart failure patients with preserved ejection fraction and without diabetes. The findings, led by Mount Sinai’s
✨ Onyx Summary Guardant Health announced its participation in two upcoming investor conferences: the Jefferies Global Healthcare Conference in London on November 19 and the Piper Sandler 37th Annual Healthcare Conference in New York on December 2. Live and archived webcasts of both fireside chats will be available on the company’
✨ Onyx Summary Seer announced that new data powered by its Proteograph Product Suite will be featured at the 2025 HUPO World Congress, highlighting how deep, scalable proteomics is advancing research in cardiovascular, oncology, and aging biology. With over a dozen scientific presentations and two invited talks, the company’s participation
✨ Onyx Summary Lexicon Pharmaceuticals reported third-quarter 2025 revenue of $14.2 million, driven by $13.2 million in licensing revenue from its Novo Nordisk agreement and $1.0 million from U.S. sales of INPEFA, narrowing its net loss to $12.8 million from $64.8 million a year earlier.
✨ Onyx Summary Rocket Pharmaceuticals reported third-quarter 2025 results, highlighting renewed FDA alignment to resume its Phase 2 pivotal study of RP-A501 for Danon disease and ongoing progress across its AAV-based cardiovascular and lentiviral hematology gene therapy programs. The company ended the quarter with $222.8 million in cash, reduced its
✨ Onyx Summary enGene Holdings announced that management will participate in three upcoming investor conferences—the Guggenheim Healthcare Innovation, Stifel 2025 Healthcare, and Jefferies Global Healthcare Conferences—throughout November 2025. Webcasts of the presentations will be available on the company’s investor website for 90 days. BOSTON & MONTREAL – enGene Holdings
✨ Onyx Summary Guardant Health granted restricted stock units representing 184,961 shares and one stock option for 5,731 shares to new non-executive employees under its 2023 Employment Inducement Incentive Award Plan, with an exercise price of $93.02 per share. The awards, approved on October 21, 2025, serve as
✨ Onyx Summary Guardant Health released new data showing that its Guardant Reveal blood test can detect chemotherapy effectiveness in patients with advanced solid tumors months earlier than conventional methods, using a tissue-free, methylation-based ctDNA tumor fraction signal. Published in the Journal of Liquid Biopsy, the study found that decreases in
✨ Onyx Summary Seer reported third-quarter 2025 revenue of $4.1 million, up 2% year-over-year, with a net loss of $18.2 million and $251.2 million in cash and investments. The company saw record adoption of its Proteograph ONE workflow and a surge in third-party publications, underscoring expanding market validation
✨ Onyx Summary Recursion reported a third-quarter 2025 net loss of $162.3 million on $5.2 million in revenue, with $667 million in cash and an expected runway through 2027. The company achieved over $500 million in cumulative upfront and milestone payments from partners Roche, Genentech, and Sanofi, advanced multiple
✨ Onyx Summary Recursion announced a leadership transition effective January 1, 2026, with Chief R&D and Commercial Officer Najat Khan, Ph.D., appointed CEO and President, succeeding Co-Founder Chris Gibson, Ph.D., who will become Chairman of the Board and interim Executive Advisor. The move, unanimously approved by the
✨ Onyx Summary Geron reported third-quarter 2025 revenue of $47.2 million, up 67% year over year, driven by continued commercialization of RYTELO for lower-risk myelodysplastic syndromes, with a net loss of $18.4 million and $421.5 million in cash. The company completed enrollment in its Phase 3 IMpactMF trial
✨ Onyx Summary Keros Therapeutics reported a third-quarter 2025 net loss of $7.3 million, significantly reduced from $53.0 million a year earlier, driven by revenue from its licensing agreement with Takeda. The company ended the quarter with $693.5 million in cash and plans to return $375 million to
✨ Onyx Summary Foghorn Therapeutics reported third-quarter 2025 collaboration revenue of $8.2 million and a net loss of $15.8 million, ending the quarter with $180.3 million in cash and a runway extending into 2028. The company advanced its oncology pipeline—including FHD-909 in Phase 1 with Lilly and
